AstraZeneca (AZ) has announced that new real-world data from Canada shows its COVID-19 vaccine – Vaxzevria – was found to be highly effective after one dose against severe disease or hospitalisation caused by the Beta and Delta variants.

The pre-print results, from the Canadian Immunization Research Network (CIRN) with support from Public Health Agency of Canada and the Canadian Institutes of Health, showed one dose of Vaxzevria was 82% effective against hospitalisation or death caused by the Beta and Gamma COVID-19 variants.

On top of that, AZ’s jab showed high efficacy against the Delta and Alpha variants, showing an 87% reduction and 90% reduction of hospitalisations or deaths respectively.

One dose of Vaxzevria had lower efficacy against milder symptomatic disease than against severe disease, although AZ added that the indicated two dose schedule of the vaccine is known to enhance efficacy in this disease setting.

The vaccine’s effectiveness against any symptomatic disease was 50% for the Beta or Gamma variants, and 70% and 72% against the Delta and Alpha variants respectively.

The analysis included 69,533 individuals who tested positive for COVID-19 from December 2020 to May 2021 in Ontario, Canada, with 28,705 testing positive for non-variants of concern and 40,828 testing positive for a variant of concern.

“With different variants threatening to disrupt our route out of the pandemic, this real-world evidence shows that Vaxzevria, along with other vaccines used in Canada, provides a high level of protection against the most serious forms of the disease, even after just one shot,” Said Mene Pangalos, executive vice president, BioPharmaceuticals R&D at AZ.

“It is essential that we continue to protect as many people as possible in all corners of the world in order to get ahead of this deadly virus,” he added.

Reference
https://www.pharmatimes.com/news/az_says_its_covid-19_vaccine_protects_against_severe_disease_caused_by_variants_1373488

More News
Maximising product potential with spray drying in CDMO
News · 02/03/2024

The pharmaceutical and biotechnology industries constantly seek innovative methods to enhance product stability, solubility, bioavailability and ease of use. Within this realm, CDMOs [Contract Development & Manufacturing Organizations] serve as invaluable partners in the development and production of high-quality drug products.

READ MORE
Chinese New Year | Red Sea crisis | Freight Rates
News · 05/02/2024

Chinese New Year 2024 is upon us, disrupting logistics from Asia starting Feb 10th. This event is expected to impact global shipping until Feb 21. Freight rates from Asia has skyrocketed with rates to the US surging by 3.5X and Europe by 6X.

READ MORE
Shipping Titans Battle Soaring Freight Expenses & Cargo Turbulence Amidst Red Sea Upheavel
News · 02/01/2024

Amid ongoing Red Sea diversions by shipping giants like Maersk, CMA, logistics managers are globally confronting a dual challenge of escalating ocean and air freight prices alongside cargo disruptions due to

READ MORE
Continuous manufacturing (CM): A game changer for pharma
News · 01/12/2023

Why will CM be the next generation on quality?

READ MORE
ICCM5 adopts new framework
News · 31/10/2023

The Fifth International Conference on Chemicals Management (ICCM5) concluded on 30 September in Bonn, Germany, by adopting “a comprehensive global framework that sets concrete targets and guidelines for key sectors across the entire lifecycle of chemicals”.

READ MORE
The Global Impact Of China’s Golden Week: Is Your Business Ready?
News · 29/09/2023

In October, the People’s Republic of China celebrates its annual national holiday, known as Golden Week. Similar to Chinese New Year, the entire country is on holiday, resulting in business closures and a potential 14-day halt in production and transportation of manufactured goods.

READ MORE
ECHA Adds Five Hazardous Chemicals To PIC
News · 08/09/2023

The European Chemicals Agency (ECHA) has amended the Prior Informed Consent (PIC) Regulation, EU 64/2012, to add 27 pesticides and eight industrial chemicals into Annex I, bringing the total to 295. As a result, EU exporters are now required to notify their intentions to export them from 1 November onwards.

READ MORE
Global Custom Synthesis & Manufacturing: Escalating Demand for Specialty Chemicals Drives Growth
News · 04/09/2023

The global custom synthesis and manufacturing market was valued at US$271.33 billion in 2022. The market value is expected to reach US$474.94 billion by 2028.

READ MORE
4 key Trends Reshaping Ocean freight Industry in 2023
News · 04/04/2023

The ocean freight industry is undergoing a massive transformation, as the technology and supply chain management tools are being improved by the day, impacting ocean freight rates.

READ MORE